Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin
| Autor: | T Hakes, William J. Hoskins, Maurie Markman, Stephen C. Rubin, Bonnie Reichman, John L. Lewis, Walter B. Jones, Lois Almadrones |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Population Ovary Second line Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Parenteral Infusions Intravenous education Etoposide Retrospective Studies Ovarian Neoplasms Cisplatin Chemotherapy education.field_of_study business.industry Cytarabine Retrospective cohort study medicine.disease Clinical trial medicine.anatomical_structure Immunology Drug Evaluation Female Neoplasm Recurrence Local business Ovarian cancer medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 9:1801-1805 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1991.9.10.1801 |
| Popis: | Phase II trials of second-line intraperitoneal (IP) cisplatin-based therapy in patients with ovarian cancer have demonstrated the ability of this approach to produce objective antitumor responses, including surgically defined complete responses (CRs), in individuals with persistent small-volume disease after front-line cisplatin-based intravenous (IV) treatment. To examine the influence of a prior response to systemic cisplatin on the activity of second-line IP cisplatin, we retrospectively analyzed two phase II trials of cisplatin-based IP therapy in persistent/recurrent ovarian cancer conducted at our institution. Of the 89 assessable patients on the two trials, 52 (58%) had previously responded to IV cisplatin. The overall response and CR rates to second-line IP cisplatin-based therapy in this previously responding population were 56% and 33%, respectively, compared with overall response and CR rates in the 37 nonresponders to IV cisplatin of 11% and 3%, respectively (P less than .001; chi 2, 1 df). In the 36 patients responding to systemic cisplatin and whose largest tumor mass measured less than 1 cm at IP cisplatin initiation, a 42% CR rate was observed, compared with a 7% CR rate in the 14 patients with the same bulk of disease who had previously failed to respond to systemic cisplatin (P less than .025). We conclude that a prior response to systemic cisplatin strongly influences the antineoplastic activity of second-line IP cisplatin in ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|